Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Ovarian Neoplasms 12Small Cell Lung Carcinoma 8Carcinoma, Ovarian Epithelial 5Uterine Cervical Neoplasms 4Neoplasms 4Neuroblastoma 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Leukemia 3Fallopian Tube Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Anemia, Refractory, with Excess of Blasts 2Thrombocytopenia 1Solid Tumors 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1SCLC, Extensive Stage 1Recurrence 1Radiation Injuries 1Primary Myelofibrosis 1Polycythemia Vera 1Peritoneal Neoplasms 1Myoepithelioma 1Myeloproliferative Disorders 1Multiple Myeloma 1Liposarcoma, Myxoid 1

Interventions

Cyclophosphamide 2sargramostim 1iberdomide 1fludarabine 1dinutuximab 1Topotecan 1Magnetic Resonance Spectroscopy 1Influenza Vaccines 1Colony-Stimulating Factors 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Ganglioneuroblastoma × Topotecan × Clear all
NCT07437963 2026-04-15

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
76 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡